公开(公告)号：US20200166525A1

公开(公告)日：2020-05-28

申请号：US16631619

申请日：2018-07-24

Applicant: Toru HASEGAWA ,  NIPRO CORPORATION

Inventor： Toru HASEGAWA ,  Hiroshi YOSHIDA ,  Yoshinori KOSOKU

IPC: G01N33/68 ,  G01N33/74 ,  G16H50/30 ,  A61B5/055 ,  A61B6/03

Abstract: Provided is a method for aiding diagnosis of a neurodegenerative disease in a subject with a light physical burden. The method for aiding diagnosis of the neurodegenerative disease, comprising: a first assessment step of assessing a risk of the neurodegenerative disease based on an amount of homocysteine acid in a biological sample obtained from the subject; a second assessment step of assessing a risk of the neurodegenerative disease based on an amount of an inflammatory factor, a pituitary gland secretion, or an autonomic nerve secretion in the biological sample obtained from the subject or based on a measured value obtained from a brain image of the subject; and a step of determining whether the subject has the neurodegenerative disease based on the results of the first assessment and the second assessment.

公开(公告)号：US20220365102A1

公开(公告)日：2022-11-17

申请号：US17764931

申请日：2020-09-02

Applicant: NIPRO CORPORATION

Inventor： Yoshinori KOSOKU ,  Yuka SANO ,  Toshiaki BABA ,  Hiroshi YOSHIDA

IPC: G01N33/68 ,  G01N33/543

Abstract: Two different antibodies that specifically bind to tau protein or phosphorylated tau protein are used. One of the two different antibodies is a first antibody immobilized on a support or labeled with a molecule capable of binding to the support, and the other of the two different antibodies is a second antibody labeled without being immobilized on the support. The tau protein includes an N-terminal domain, a C-terminal domain, and an intermediate domain located between the N-terminal and C-terminal domains. Epitopes recognized by the first and second antibodies are each an amino acid sequence contained in the intermediate domain or an amino acid sequence contained in the N-terminal domain. One of the first and second antibodies is first subjected to an antigen-antibody reaction with the blood sample, and the other of the first and second antibodies is subsequently subjected to an antigen-antibody reaction with the blood sample.

公开(公告)号：US20220283186A1

公开(公告)日：2022-09-08

申请号：US17638044

申请日：2020-08-28

Applicant: NIPRO CORPORATION

Inventor： Hiroshi YOSHIDA ,  Yoshinori KOSOKU ,  Yuka SANO

IPC: G01N33/68

Abstract: The present disclosure provides a method for detecting Alzheimer's cognitive impairment or mild cognitive impairment, comprising: measuring an amount of homocysteic acid in a biological sample from a subject who suffers or possibly suffers from a neurological disease, and detecting Alzheimer's cognitive impairment or mild cognitive impairment based on the measured amount of the homocysteic acid.